A WHO guideline on GLP-1 medicines has many families asking what it means for their kids. Here are the ten questions to bring to the pediatrician, and how to check each answer.
If you've seen headlines about GLP-1 for children after a WHO guideline, take a breath before you panic or celebrate. Start with the document itself. The exact title, the publication date, and the age group covered matter more than most headlines, because news coverage tends to blur all three together. This post won't tell you what's right for your child, but it can help you walk into the appointment with sharper questions.
What the WHO guideline actually says, and what it does not
Start on the WHO publications page at who.int. Open the guideline PDF and read the front matter for its exact title and publication date. The scope section tells you which population the recommendation covers. If it's written for adults, that matters a lot for a teenager, and you should ask your pediatrician how they read that gap.
WHO recommendations come in two strengths. A strong recommendation means the panel judged that benefits clearly outweigh harms for most people in the group. A conditional recommendation means the balance depends more on context, personal values, and available resources. In practice, a conditional recommendation invites a shared decision rather than a standard prescription. Each recommendation also comes with a rating of how certain the evidence is. Look for that rating in the evidence summary, because it shows how much confidence the panel placed in the data behind its advice.
A guideline is not a drug label. A WHO recommendation doesn't mean a medicine is approved for a given age in your country. Approval comes from national regulators, such as ANVISA in Brazil or the FDA in the United States. Each one reviews its own label, with its own age limits and indications, and that label sets the approved uses in that country.
How pediatric obesity is diagnosed
Adult BMI cutoffs don't work well for kids. Children grow and change shape constantly, so clinicians compare a child's BMI with reference curves built by age and sex. The WHO growth reference for ages 5 to 19 is an international standard, and it's free on the WHO website. In the United States, the CDC growth charts use the same age and sex logic, so American families can see where their child falls among peers.
Two terms show up often. A percentile shows where the child's BMI falls among children of the same age and sex. A z-score measures how far the child sits from the median, in standard deviation units. Z-scores are easier to compare across visits, which is why many clinics prefer them. Find out which one your pediatrician uses, and which cutoffs your local pediatric society applies to define obesity.
Weight alone doesn't tell the whole story. Pediatricians often check blood pressure, blood glucose, lipids, liver fat, and sleep, including snoring that may point to sleep apnea. Those results shape how urgent the situation is and what kind of care fits best. They also give you a baseline for later comparisons.
Which drugs have pediatric data, and what the trials measured
Pediatric labels vary a lot from product to product, so an adult approval doesn't carry over to teens automatically. In the United States, liraglutide and semaglutide have labels for adolescents with obesity, and several GLP-1 products carry labels for youth with type 2 diabetes. Tirzepatide has pediatric studies, and its label status changes as new results come in. Check the current label on DailyMed for the exact age range of each product, and read the indications section, not just the marketing summary. Our tirzepatide archive at TirzeBlog collects summaries of published studies, but those summaries never replace the label.
Studies in teens with obesity usually measure change in BMI or percentage of body weight lost. Studies in young people with type 2 diabetes focus more on blood sugar markers, and their doses and endpoints often differ. Mixing the two groups makes results hard to read, so check which population each study enrolled.
Those outcomes matter, but they have limits. They can show short-term changes in weight and metabolic markers. They usually don't capture long-term growth, final adult height, or cardiovascular outcomes decades later. When you read a trial, look up its ClinicalTrials.gov registration. Check the design, how long it ran, how many people took part, and whether it was published in a peer-reviewed journal. A short trial simply can't answer a long-term question.
Safety questions that deserve a written answer
Gastrointestinal effects are the most commonly reported. Nausea, vomiting, diarrhea, constipation, and abdominal pain can appear, especially during dose increases. A good team will explain how they track these symptoms, how often they'll check in, and what to do if they linger.
Current labels carry warnings about pancreatitis and gallbladder disease, including gallstones. Products in this class also carry a boxed warning about thyroid C-cell tumors, including medullary thyroid carcinoma. The label contraindicates use in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). Write your family history down before the first visit, and ask the team to record it in the chart. Then read the Warnings and Precautions section of each product's current label, since the wording differs.
Monitoring deserves a plan too. Get a schedule that covers height, pubertal development, and mood or behavior changes, based on the manufacturer's recommendations and your local health service protocols. Those three areas are easy to overlook when everyone's attention stays on the scale.
Building the family side of the decision
Before any medicine, guidelines and specialists generally expect a structured plan. That usually means nutrition support, regular physical activity, psychological support when needed, and scheduled follow-up. Medication sits inside that plan, not in place of it. Have the team spell out each piece for your child in concrete steps rather than general advice.
Your routine changes too. Expect more appointments, periodic blood work, and possibly other exams. Find out the total cost, whether your health plan covers both the medicine and the visits, whether prior authorization applies, and what happens if you need to pause. A planned pause can be a reasonable choice, and learning the rules upfront makes it less stressful later. Get your local service's visit frequency and your plan's coverage rules in writing.
Tracking helps everyone in the room. Keep a simple log with weight taken at the same time each week, sleep hours, appetite on a 1 to 5 scale, mood, and any side effects. Bring it to every visit so decisions rest on data rather than memory. If you want more ideas for keeping this record without turning daily life into homework, our notes on tracking progress at TirzeBlog cover that.
The ten questions and how to use them
Bring these questions to the appointment, tick off each answer, and write the answers down.
- Diagnosis: Which growth chart and BMI measure do you use for my child, and which cutoff defines obesity locally?
- Diagnosis: Which checks, such as blood pressure, glucose, liver, and sleep, are already done, and which are still pending?
- Evidence: Which studies support this medicine at my child's age, and did they enroll teens with obesity or youth with type 2 diabetes?
- Evidence: What did the trials measure, and which long-term questions remain open?
- Safety: Which side effects are we likely to see, and how will the team track them?
- Safety: How do the label warnings apply to our family history, including any thyroid cancer or MEN2?
- Routine: How many visits should we plan for, which tests are scheduled, and who watches growth, puberty, and mood?
- Routine: What will this cost, what does our plan cover, and does it require prior authorization?
- Alternatives: Which nutrition, activity, and psychological steps belong to the plan, and what happens if they fall short?
- Alternatives: What criteria start treatment, what criteria stop or pause it, and who follows my child between visits?
The alternatives questions carry real weight, because a medicine should never be the only option on the table. They show whether the team has a plan for when things go well, when progress stalls, and when treatment should stop. Then request the plan, the goals, and the reevaluation date in writing. A written plan gives every adult in the room the same reference point and makes it easier to see whether things are actually working. For sources to bring along, the TirzeBlog homepage (https://tirzeblog.com) links to our notes, and the WHO publications page, your country's regulator, and ClinicalTrials.gov let you check the originals yourself.
FAQ
Is tirzepatide approved for children?
It depends on the country and the indication. Check the current label on your regulator's website or on DailyMed, since pediatric labels change as new trials report results.
Does the WHO guideline mean my child can start a GLP-1 medicine now?
No. A guideline is advice for clinicians and health systems, not a prescription. Your child still needs an individual evaluation, a check of the approved age range in your country, and a plan that includes nutrition, activity, and follow-up.
What side effects are most common in teens?
Gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation are reported most often. Ask your pediatrician how symptoms will be tracked and what to do if they last.
Should we get the plan in writing?
Yes. The written plan should list the goals, the criteria to start or stop, who monitors your child, and the date of reevaluation.
Sources
Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Always consult your doctor before starting, changing or stopping any treatment.
Ozempro — Monitor GLP-1
Never miss a dose and track everything
Injection reminders, a dose history and a side-effects diary — all organized to bring to your appointment.
or download the app
